Creative Planning
BBIO icon

Creative Planning’s BridgeBio Pharma BBIO Stock Holding History

Creative Planning’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.89M Buy
119,661
+9,018
+8% +$654K 0.01% 775
2025
Q4 		$8.46M Buy
110,643
+16,787
+18% +$1.1M 0.01% 690
2025
Q3 		$4.87M Buy
93,856
+18,568
+25% +$906K ﹤0.01% 902
2025
Q2 		$3.25M Buy
75,288
+13,924
+23% +$506K ﹤0.01% 985
2025
Q1 		$2.12M Buy
61,364
+17,433
+40% +$588K ﹤0.01% 1136
2024
Q4 		$1.21M Buy
43,931
+12,667
+41% +$327K ﹤0.01% 1499
2024
Q3 		$772K Buy
+31,264
New +$821K ﹤0.01% 1731
2024
Q1 		– Sell
-5,033
Closed -$203K – 2928
2023
Q4 		$203K Buy
+5,033
New +$151K ﹤0.01% 2419

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's BBIO Position: Q1 2026 in Review

Creative Planning increased its BridgeBio Pharma (BBIO) stake by 8.2% in Q1 2026, buying an estimated $654K and bringing the position to 119,661 shares worth $8.89M. The position accounts for 0.01% of the portfolio, ranked #775.

Creative Planning first reported a position in BBIO in Q4 2023 and has held it in 8 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Creative Planning held 119,661 shares of BridgeBio Pharma worth $8.89M as of Q1 2026.
  • Creative Planning bought 9,018 BridgeBio Pharma shares in Q1 2026, an estimated $654K.
  • BridgeBio Pharma made up 0.01% of Creative Planning's portfolio in Q1 2026, its #775 holding.
  • Creative Planning first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 8 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.